The FDA has approved Pretomanid, an oral tablet for highly treatment-resistant forms of tuberculosis of the lungs.
The drug is approved for use in combination with bedaquiline and linezolid. It targets drug-resistant, treatment-intolerant or multidrug-resistant TB in adult patients.
"The threat of antimicrobial-resistant infections is a key challenge we face as a public health agency," said FDA Principal Deputy Commissioner Amy Abernethy, MD, PhD. "The bacterium that causes tuberculosis can develop resistance to the antibiotics used to treat it. Multidrug-resistant TB and extensively drug-resistant TB are public health threats due to limited treatment options. New treatments are important to meet patient national and global health needs."